The Centers for Medicare & Medicaid Services (CMS) has proposed to eliminate a streamlined pathway for new medical technologies seeking supplemental Medicare payments. This alternative pathway, established in 2021, allowed devices with FDA Breakthrough Device designation to bypass a full substantial clinical improvement review. CMS now argues that many devices approved through this expedited route have not proven to offer significant clinical advantages in practice, leading to a reconsideration of the process. AI
RANK_REASON The cluster discusses a proposed regulatory change by a major government agency impacting the healthcare industry. [lever_c_demoted from significant: ic=1 ai=0.1]
- Centers for Medicare & Medicaid Services
- FDA Breakthrough Device designation
- Medicare
- Food and Drug Administration
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
